Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Study product, Placebo.
- Who it may be relevant to
- Registry conditions: Atopic Dermatitis, Eczema. Basic parameters: 3 months — 12 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Poland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis - Study Vs Placebo -- Use Test Under Dermatological Control -
Overview
Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities. The aim of this study is to assess the efficacy of a product for atopic skin versus a placebo. Primary objectives include assessing the number, the delay and severity of recurrences of atopic dermatitis (measured by the SCORAD score), and the evolution of symptoms such as dryness and pruritus. Secondary objectives include quality of life and quality of sleep and skin acceptability. The study protocol is a multicenter, double-blind, randomized clinical trial, in which participants receive either the study product or a placebo, while continuing their topical corticosteroid treatment.
Interventions
- Other Study product
Anti-itching, anti-replapse and repairing treatment. Emollient. - Other Placebo
Emollient
Primary outcome measures
- SCOring Atopic Dermatisis (SCORAD) [Time frame: Before (Day-X) and after the products use (Day 0, Month 2, Month 4 and Month 6)]
- SCORING ATOPIC DERMATITIS BY SUBJECT'S PARENT/LEGAL GUARDIAN (PO-SCORAD) [Time frame: Before (Day -X) and after the products use (Day 0, Month 2, Month 4 and Month 6)]
- CUTANEOUS ACEPTABILITY [Time frame: On Day 0, Month 2, Month 4 and Month 6 of the product use, the body and face of the subject is examined by the dermatologist in charge of the study.]
- Evaluation of "xerosis", "pruritus" and "insomnia" evolution based on SCORAD [Time frame: Before (Day-X) and after the products use (Day 0, Month 2, Month 4 and Month 6)]
Eligibility criteria
Inclusion criteria
Specific
- Sex: female and/or male;
- Age: from 3 months up to 12 years old;
- Phototype: I to IV;
- 100% with atopic skin;
- 100% with sensitive skin;
- Subject who had at least 3 eczema flares-up of atopic dermatitis during the last 6 months before start of the study, including the crisis observed on D-X.
- Subject presenting on the visit D-X a flare-up of eczema for which the dermatologist prescribed treatment with topical corticosteroids treatment;
- Subjects with SCORAD between 15 and 40 on D-X;
- Subject who do not require medical treatment anymore after using prescribed topical corticosteroids from D-X up to D0 and clinical signs of atopic dermatitis are resolved, to be defined on D0 visit (in case of insufficient healing of inflammatory lesions, the subject continues medical treatment as recommended by the investigator).
General
- Healthy subject;
- Child whose at least one parent/legal guardian has given freely and expressly her/his informed consent;
- Child whose at least one parent/legal guardian is willing to adhere to the protocol and study procedures;
- Polish citizenship.
Exclusion criteria
- Cutaneous pathology on the study zone other than atopic dermatitis;
- Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the efficacy of the study products, including anti-histaminic treatment (except prescribed dermocorticoids on D-X and in case of flare-up during the study course);
- Subject having undergone a surgery under general anesthesia within the previous month;
- Excessive exposure to sunlight or UV-rays within the previous month;
- Subject enrolled in another clinical trial during the study period (concerns the studied zones);
- Subjects presenting oozing eczema lesions or any sign of infection on eczema lesions (e.g; pus).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Poland · 1 center
- EUROFINS — Gdansk
Identifiers
NCT: NCT06756438 · RC2024PSaib+PL